Abstract
Glioblastoma multiforme (GBM) is one of the most malignant cancers in human brain. The prognosis of GBM is extremely poor because it is resistant to radiotherapy and chemotherapy. Improving understanding of the tumor biology brings some new hope to the treatment of GBM. In this review, we discuss the evidence that FoxM1 promotes the development and progression of GBM by regulating key factors involved in cell proliferation, epithelial to mesenchymal transition (EMT), invasion, angiogenesis and upregulating Wnt/β-catenin signalling. Our recent experimental findings are also summarized to prove that FoxM1 is a novel therapeutic target against GBM.
Keywords: Glioblastoma, tumorigenesis, EMT, invasion, angiogenesis, FoxM1, Wnt/β-catenin signaling.
Current Pharmaceutical Design
Title:Glioblastoma Multiforme Formation and EMT: Role of FoxM1 Transcription Factor
Volume: 21 Issue: 10
Author(s): Zhongyong Wang, Sicong Zhang, Timothy L Siu and Suyun Huang
Affiliation:
Keywords: Glioblastoma, tumorigenesis, EMT, invasion, angiogenesis, FoxM1, Wnt/β-catenin signaling.
Abstract: Glioblastoma multiforme (GBM) is one of the most malignant cancers in human brain. The prognosis of GBM is extremely poor because it is resistant to radiotherapy and chemotherapy. Improving understanding of the tumor biology brings some new hope to the treatment of GBM. In this review, we discuss the evidence that FoxM1 promotes the development and progression of GBM by regulating key factors involved in cell proliferation, epithelial to mesenchymal transition (EMT), invasion, angiogenesis and upregulating Wnt/β-catenin signalling. Our recent experimental findings are also summarized to prove that FoxM1 is a novel therapeutic target against GBM.
Export Options
About this article
Cite this article as:
Wang Zhongyong, Zhang Sicong, Siu L Timothy and Huang Suyun, Glioblastoma Multiforme Formation and EMT: Role of FoxM1 Transcription Factor, Current Pharmaceutical Design 2015; 21 (10) . https://dx.doi.org/10.2174/1381612821666141211115949
DOI https://dx.doi.org/10.2174/1381612821666141211115949 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Regenerative Potential Combined with Nanotechnology and Tissue Engineering for Myocardial Regeneration
Current Stem Cell Research & Therapy Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Antimicrobial and Cytotoxicity Activities of 2-(aryl)-3-(benzo[d][1,3] dioxol-5-yl)thiazolidin-4-ones
Letters in Drug Design & Discovery Identification of WHO II/III Gliomas by 16 Prognostic-related Gene Signatures using Machine Learning Methods
Current Medicinal Chemistry Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer
Current Immunology Reviews (Discontinued) Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery Bioactivity of Hybrid Polymeric Magnetic Nanoparticles and Their Applications in Drug Delivery
Current Pharmaceutical Design A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances
Current Molecular Pharmacology MicroRNA-34b Inhibits Pancreatic Cancer Metastasis Through Repressing Smad3
Current Molecular Medicine Glucose Transporters Regulation on Ischemic Brain: Possible Role as Therapeutic Target
Central Nervous System Agents in Medicinal Chemistry Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?
Current Medicinal Chemistry The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Current Gene Therapy Research Advances in the Treatment of Melanoma by Treat Melanoma
Current Topics in Medicinal Chemistry Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery